Zydus Lifesciences (ZYDUSLIFE) — Announcement

📢 Key Event
Zydus reports positive Phase II(b) topline results for Saroglitazar in MASH

💡 Investor Takeaway
The results validate Saroglitazar's potential as a first-in-class MASH therapy with a clear path toward regulatory submissions and commercialization.

Zydus Lifesciences announced positive topline results from its completed EVIDENCES-X Phase II(b) trial of Saroglitazar Magnesium for MASH, showing 26.5% treatment difference in meeting the primary endpoint of steatohepatitis resolution without fibrosis worsening. The global study enrolled 189 patients across three countries and met secondary endpoints including liver histology improvements. Results will be presented at upcoming scientific meetings and submitted for publication, reinforcing the company's pipeline progress in addressing the significant unmet need in metabolic liver disease treatment.

📄 View Original Announcement (PDF)

📊 Stock Analysis — ZYDUSLIFE ✨ Ask AI About This

About Zydus Lifesciences Ltd (ZYDUSLIFE)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹1,15,919.92 Cr P/E: 25.9 ROE: 16.6% ROCE: 16.8% Div Yield: 0.09%

View full ZYDUSLIFE stock details →

📡 Get AI alerts when ZYDUSLIFE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ZYDUSLIFE — Free

💡 Ask AI about this filing

"When will full trial data be presented at scientific meetings?" "What is the timeline for FDA submission of EVIDENCES-X results?" "How does Saroglitazar's efficacy compare to existing MASH therapies in development?"

Ask AI Free →

📊 More ZYDUSLIFE filings

See all ZYDUSLIFE filings →

🔥 Also filed on 31 August 2026

DCBBANK DCB Bank Ltd Corporate Action JKIL J Kumar Infraprojects Ltd Annual Report 514470 Winsome Textile Industries Ltd Annual Report 523896 AVI Products India Ltd Annual Report ARKADE Arkade Developers Ltd Annual Report SIGMA Sigma Solve Ltd Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ZYDUSLIFE files new disclosures

Track ZYDUSLIFE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ZYDUSLIFE — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd